Optimization of Luminescent Assay for Screening of Cyclin-Dependent Kinase 2 Inhibitors

被引:2
|
作者
Suthar, M. P. [1 ]
Patel, M. M. [2 ]
机构
[1] Ganpat Univ, Shree SK Patel Coll Pharmaceut Educ & Res, Dept Biotechnol, Kherva 382711, India
[2] Kalol Inst Pharm, Kalol 382721, India
关键词
Cyclin-dependent kinase 2; histone H1; luminescence; assay; optimization; PROTEIN-KINASES;
D O I
10.4103/0250-474X.70472
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Cyclin-dependent kinases are most extensively studied targets for cancer chemotherapy since the tumor cells exhibit false checkpoints and can proliferate even if the genome is compromised. Cyclin-dependent kinases ensure the tight regulation of the cell cycle execution by mediating phosphorylation of cellular proteins. Deregulation of the cyclin-dependent kinase 2 activity by cellular and external factors leads to many diseases like cancers. Different methods like radiolabeled, fluorescence and luminescence are available for screening of library of compounds against kinases. However, bioluminescent methods offer several advantages like low background and no effect of fluorescent compound interference. Present study is focused on development, optimization and validation of cyclin-dependent kinase 2 assay which is suitable for identification potent and selective, ATP competitive and non-competitive inhibitors of cyclin-dependent kinase 2. The aim of present investigation was to optimize the assay for cyclin-dependent kinase 2/cylin A and cyclin-dependent kinase 2/cyclin E with use of bioluminescence based biochemical reaction. Both cyclin-dependent kinase 2 which are cyclin-dependent kinase 2/cyclin A and cyclin-dependent kinase 2/cyclin E complexes, have different affinity for ATP. Therefore, both isoform analogs of cyclin-dependent kinase 2 were optimized separately. Optimum cyclin-dependent kinase 2/cyclin A and cyclin-dependent kinase 2/cyclin E concentration were found to be 250 ng/well and 200 ng/well, respectively. Optimum substrate (histone H1) concentration was found to be 2.5 mg/ml for both cyclin-dependent kinase 2 analogs. Optimum reaction time was found to be 20 min for both cyclin-dependent kinase 2/cyclin complexes.
引用
收藏
页码:290 / 294
页数:5
相关论文
共 50 条
  • [1] Cyclin-dependent kinase inhibitors
    Westwell, A
    DRUG DISCOVERY TODAY, 2001, 6 (09) : 491 - 491
  • [2] Cyclin-dependent kinase inhibitors
    Dai, Y
    Grant, S
    CURRENT OPINION IN PHARMACOLOGY, 2003, 3 (04) : 362 - 370
  • [3] Cdk pathway: Cyclin-dependent kinases and cyclin-dependent kinase inhibitors
    Gitig, DM
    Koff, A
    MOLECULAR BIOTECHNOLOGY, 2001, 19 (02) : 179 - 188
  • [4] Cdk pathway: Cyclin-dependent kinases and cyclin-dependent kinase inhibitors
    Diana M. Gitig
    Andrew Koff
    Molecular Biotechnology, 2001, 19 : 179 - 188
  • [5] Novel cyclin-dependent kinase inhibitors
    Westwell, AD
    DRUG DISCOVERY TODAY, 2001, 6 (13) : 701 - 701
  • [6] INHIBITORS OF CYCLIN-DEPENDENT KINASE AND CANCER
    BIGGS, JR
    KRAFT, AS
    JOURNAL OF MOLECULAR MEDICINE-JMM, 1995, 73 (10): : 509 - 514
  • [7] Cyclin-dependent kinase inhibitors and hepatocarcinogenesis
    Hui, AM
    Sakamoto, M
    Kanai, Y
    Ino, Y
    Gotoh, M
    Hirohashi, S
    RECENT ADVANCES IN GASTROENTEROLOGICAL CARCINOGENESIS I, 1996, : 481 - 485
  • [8] Expression of cyclins, cyclin-dependent kinases and cyclin-dependent kinase inhibitors in oligodendrogliomas in humans
    Fiano, V
    Ghimenti, C
    Schiffer, D
    NEUROSCIENCE LETTERS, 2003, 347 (02) : 111 - 115
  • [9] Cyclin-dependent kinase inhibitors for treating cancer
    Toogood, PL
    MEDICINAL RESEARCH REVIEWS, 2001, 21 (06) : 487 - 498
  • [10] Cyclin-Dependent Kinase 2 Inhibitors in Cancer Therapy: An Update
    Tadesse, Solomon
    Caldon, Elizabeth C.
    Tilley, Wayne
    Wang, Shudong
    JOURNAL OF MEDICINAL CHEMISTRY, 2019, 62 (09) : 4233 - 4251